ACTRN12623000438651
Recruiting
未知
The evaluation of treatment outcomes for methamphetamine dependence in Aotearoa New Zealand
niversity of Auckland0 sites320 target enrollmentMay 1, 2023
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Substance Dependence
- Sponsor
- niversity of Auckland
- Enrollment
- 320
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Methamphetamine is the main drug of concern
- •Participants are aged 18 years of age or over
- •Participants have no severe cognitive disability that may affect their capacity to take part
- •Participants live in the Northland, Auckland, or Waikato regions of New Zealand.
- •Participants in the in\-treatment\-group will include those who have been admitted to treatment within the last two weeks of been screened for the study.
- •Participants in the Not\-In\-Treatment\-Group \[NITG] will include those who at the time of screening where not involved in formal treatment. NITG participants at screening will need to score 4 or more on the Severity of Substance Dependence Scale (SDS)
Exclusion Criteria
- •People who, in the last 30 days, have received any treatment for methamphetamine /amphetamine use, any in\-patient drug treatment or imprisonment. NB: Participants in treatment will not be eligible to participate in this study if they received any treatment for methamphetamine /amphetamine use (any in\-patient drug treatment or imprisonment, in the 30 days prior to starting the current treatment episode).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
The effect of magnesium in patients with attention deficit hyperactivity disorderIRCT20160813029327N19Islamic Azad University62
Active, not recruiting
Phase 1
Etude d’efficacité et d’acceptabilité du méthylphénidate dans les troubles de la marche de la maladie de Parkinson : Etude multicentrique en double aveugle versus placebo. - PARGKAIT IIEUCTR2008-005801-20-FRCentre Hospitalier Régional et Universitaire de Lille69
Active, not recruiting
Not Applicable
To evaluate the effectiveness of MetaDerm Cream in Atopic DermatitisCTRI/2017/06/008950Haus Bioceuticals Inc
Completed
Phase 4
A clinical trial to study the effects of two drugs, Metformin Immediate Release and Metformin Extended Release in newly diagnosed type 2 diabetes mellitus patients.Health Condition 1: E119- Type 2 diabetes mellitus without complicationsCTRI/2021/04/033194Bangalore Medical College and Research Institute70
Recruiting
Phase 3
Metformin and Body Mass Index of Patients under Treatment with SSRICondition 1: Obesity. Condition 2: Depression. Condition 3: Anxiety Disorders.Drug-induced obesityMajor depressive disorder, single episode, severe without psychotic featuresOther anxiety disordersE66.1F32.2IRCT20140102016035N3Rasht University of Medical Sciences60